

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): March 16, 2011

INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
**(State or other jurisdiction
of incorporation)**

000-51891
**(Commission
File Number)**

20-4494098
**(IRS Employer
Identification Number)**

5950 Priestly Drive, Carlsbad, California 92008
(Address of principal executive offices, including zip code)

(760) 940-6383
(Registrant's telephone number, including area code)

2595 Jason Court, Oceanside CA 92056
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

International Stem Cell Corporation is providing a copy of slides used in presentations to investors, analysts, stockholders and other interested parties.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) 99.1 Slides used in presentations.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

International Stem Cell Corporation

By: /S/ RAY WOOD
Ray Wood
Chief Financial Officer

Dated: March 16, 2011



(ISCO.OB)
**A New Kind of Stem Cell
Company**

Superior Technology
Superior Business Model
Superior Execution

Forward-looking statements


Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

The Traditional Approach


--Pick A Disease—

--Spend a Lot of Money—

--Hope for a Cure and FDA Approval--




The ISCO Model – Multiple Chances to Succeed




Parthenogenesis – Solving Ethical and Immune Matching Problems

Normal fertilization



Parthenogenesis



Categories of Human Stem Cells

	hpSCs	Embryonic	iPS	Adult SCs
Ethics (Relative to destruction of viable human embryos)	No viable embryo	Destroys viable embryo	No embryo	No embryo
Immune matching and cell banking (practical source of cells)	Population groups & individuals (♀)	Impractical (each line is unique)	Matched to individual only	Matched to individual only
Pluripotency (Become cells from all parts of body)	Yes	Yes	Yes	No
Proliferation (Ease of expansion in culture)	Strong	Strong	Strong	Weak
Genetic Manipulation (Restructuring of gene expression patterns)	Minimal	Minimal	Substantial	Minimal
Application for Diseases with Genetic Component	Superior	Superior	Deficient (carry damaged gene)	Deficient (carry damaged gene)


Prioritized Therapeutic Areas



🕒 **Cornea transplant**

- 10M corneally blind
- Untouched Asian/Indian markets
- Can use either hpSCs or hESs

🕒 **Toxicity testing**




🕒 **Retinal conditions - cell therapy is proven**

- Age-related macular degeneration (AMD)
- Retinitis pigmentosa (RP)-100,000 Americans and no therapy

🕒 **ISCO RPE technology**

- Demonstrated morphology, markers and pigmentation
- In vivo functionality testing underway




🕒 **Liver diseases (acute and chronic)**

- 30-40M with fatty liver and app. 30,000 deaths annually in the US
- 15,750 on liver waiting list (\$200-\$300k surgery, \$12-20k annually)

🕒 **ISCO hepatocyte technology**

- Demonstrated markers and functionality
- In vivo functionality testing underway



🕒 **Neurodegenerative diseases**

- Cell therapy proven
- Large unmet medical need
- Increasing with the aging of the population

🕒 **ISCO objectives**

- Development of neuronal lineages
- In vivo functional validation

Universal Stem Cell Banking

❶ Every person has an immune type



- There are 200 common types in a typical population

❷ Parthenogenetic stem cells:

- Can be matched to millions of people
- Example: 5 cell lines could match 42 million in the USA

❸ A “Bank” of these could provide immune-matched cells for millions at a cost they could afford

For the Scientist



• Biomedical Products

- >130 Products: growth factors, media and human cells
- More new products in 2009-10 than the market-leader
- cGMP media and cell manufacturing capacity




○ Applications

- Across therapeutic areas
- Regenerative medicine (Stem Cell Products)
- Safety and toxicology
- Basic cell biology

○ Commercialization

- Direct sales from in-house staff (USA)
- International Distribution: : Europe, Asia (incl.India)
- OEM Partners: ATCC, Millipore, Life Technologies






Lifeline Skin Care

Development

- Built on ISCO's scientific expertise
- Leverages proprietary technology platform
- Clinically tested for safety and efficacy

Commercialization

- Market-differentiating stem cell technology
- Direct-to-consumer and retail sales
- Specialty distributor channels
- Strategic marketing partnership



12-month Targets

☉ Lifeline Cell Technology

- Expand Product Line, Foreign Manufacturing, and Distribution Base

☉ Lifeline Skin Care

- Expand Sales Channels and Manufacturing Capacity

☉ Therapeutic Development

- Animal Studies and IND Plan

☉ International Partnering

- One or More Therapeutic Partnerships

☉ Human Parthenogenetic Stem Cell Bank

- Created Multiple cGMP Parthenote Lines

Management

🕒 **Kenneth Aldrich, JD, Executive Chairman**

- 30 years investment in and management of public and private companies

🕒 **Dr. Andrey Semechkin, CEO**

- PhD, Member of Russian Academy of Sciences
- Successful founder and manager of international companies

🕒 **Brian Lundstrom, President**

- Novo Nordisk, SangStat/Genzyme and ACADIA
- 25 years clinical-commercial development and transactional experience

🕒 **Jeffrey Janus, SVP and CEO Lifeline Cell Technology**

- 25 years experience with cell-based and FDA-compliant biological products
- Founder of Clonetics (now research product market leader Lonza)

🕒 **Dr. Ruslan Semechkin, VP and CEO Lifeline Skin Care**

- PhD, medical science and cosmeceutical development experience

🕒 **Dr. Simon Craw, VP**

- PhD, Executive with Merck, AstraZeneca and Novartis
- 22 years scientific operational experience

Financial overview

Shares outstanding

72 million

Stock price (3-3-11)

\$1.50

Market capitalization

\$108 million

**Product revenue (Q-3, 2010
annualized)**

\$1.4 million



Contact information

www.internationalstemcell.com

Kenneth Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com